Stockscreener 앱 받기
177.79
5.90%
9.91
전일 마감가:
$167.88
열려 있는:
$170.06
하루 거래량:
243.91K
Relative Volume:
1.00
시가총액:
$6.67B
수익:
-
순이익/손실:
$-62.39M
주가수익비율:
-92.61
EPS:
-1.9198
순현금흐름:
-
1주 성능:
-5.45%
1개월 성능:
-2.74%
6개월 성능:
+172.94%
1년 성능:
+197.31%
1일 변동 폭
$167.90
$179.11
1주일 범위
$167.59
$192.28
52주 변동 폭
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
177.79 | 6.30B | 0 | -62.39M | 0 | -1.9198 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com Nigeria
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com
Belite Bio Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com India
Belite Bio (NASDAQ:BLTE) Shares Down 8.6%What's Next? - MarketBeat
Belite Bio to Participate in the Leerink Global Healthcare Conference - wjfw.com
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win - TipRanks
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Exploring Belite Bio's Earnings Expectations - Sahm
Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter ... - Caledonian Record
China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Belite Bio, Inc (BLTE) Stock Report: Analyst Ratings Signal Strong Buy with 9.62% Potential Upside - DirectorsTalk Interviews
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Sees Large Growth in Short Interest - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January - MarketBeat
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio, Inc (BLTE) Stock Analysis: Biotechnology Innovator With 4.98% Potential Upside - DirectorsTalk Interviews
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - Sahm
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio completes enrollment in phase 2/3 STGD1 drug trial - Investing.com India
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
Belite Bio (NASDAQ:BLTE) Now Covered by Bank of America - Defense World
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Belite Bio Surges on Breakthrough Eye Drug Hopes - TipRanks
Belite Bio stock hits all-time high at $170.35 - Investing.com
Belite Bio stock hits all-time high at $170.35 By Investing.com - Investing.com UK
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com Canada
BofA Securities initiates coverage on Belite Bio stock with Buy rating By Investing.com - Investing.com South Africa
Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics - Barchart.com
Avoiding Lag: Real-Time Signals in (BLTE) Movement - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):